OptiNose(OPTN) - 2024 Q2 - Quarterly Results

Optinose Reports Second Quarter 2024 Financial Results and Recent Operational Highlights Company reports Q2 2024 XHANCE net revenue of $20.5 million, an increase of 5% compared to Q2 2023 XHANCE has been added to Express Scripts' national formularies, among the largest commercial formularies in the U.S. with more than 24 million lives. Company narrows full year 2024 XHANCE net revenue guidance to be between $85.0 to $90.0 million and increases expected average net revenue per prescription guidance to be at ...